GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies
News Dec 20, 2006
Illumina, Inc. has announced that it entered into a multi-million dollar agreement with GlaxoSmithKline (GSK) for the purchase of 1,000 HumanHap550 BeadChips to be run at an undisclosed third-party facility and the addition of a statement of work to utilize Illumina's Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application.
According to Illumina, by the end of 2006, it will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK.
"This purchase follows shortly after GlaxoSmithKline expanded their initial scope of work for a multi-year, genotyping services agreement with Illumina, demonstrating their continued uptake of our technology," said Jay Flatley, Illumina President and Chief Executive Officer.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.